{"id":"sofosbubir-velpatasvir-voxilaprevir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Asthenia"}]},"_chembl":{"chemblId":"CHEMBL3545062","moleculeType":"Small molecule","molecularWeight":"883.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Voxilaprevir inhibits the NS3/4A serine protease. Together, these three agents target complementary steps in the HCV life cycle, providing a pangenotypic direct-acting antiviral regimen.","oneSentence":"This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:53.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vosevi"],"phase":"marketed","status":"active","brandName":"sofosbubir/velpatasvir/voxilaprevir","genericName":"sofosbubir/velpatasvir/voxilaprevir","companyName":"Partners in Health","companyId":"partners-in-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}